• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Geron Corporation (Amendment)

    2/3/23 5:27:19 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email
    SC 13D/A 1 geo17-geron_18693.htm GROWTH EQUITY OPPORTUNITIES 17, LLC -- SCH 13D/A(#1E) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Geron Corporation

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    374163103

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    January 27, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 374163103

    13D Page 2 of 10 Pages    

    Schedule 13D

     

    Item 1.Security and Issuer.

     

    This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D amends and supplements the Schedule D originally filed on June 4, 2020 and relates to the common stock, $0.001 par value (the “Common Stock”), of Geron Corporation (the “Issuer”), having its principal executive office at 919 E. Hillsdale Blvd., Suite 250, Foster City, California 94404.

     

    Certain terms used but defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

     

    Item 2.Identity and Background.

     

    This statement is being filed by:

     

    (a) Growth Equity Opportunities 17, LLC (“GEO”);

     

    (b) New Enterprise Associates 17, L.P. (“NEA 17”), which is the sole member of GEO; NEA Partners 17, L.P. (“NEA Partners 17”), which is the sole general partner of NEA 17; and NEA 17 GP, LLC (“NEA 17 LLC” and, together with NEA Partners 17, the “Control Entities”), which is the sole general partner of NEA Partners 17; and

     

    (c) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Liza Landsman (“Landsman”), Mohamad H. Makhzoumi (“Makhzoumi”), Edward T. Mathers (“Mathers”), Scott D. Sandell (“Sandell”), Peter W. Sonsini (“Sonsini”), Paul Walker (“Walker”) and Rick Yang (“Yang”) (together, the “Managers”) and Joshua Makower (“Makower”). The Managers are the managers of NEA 17 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of GEO, NEA 17 and each Control Entity is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Behbahani and Mathers is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Baskett, Chang, Makhzoumi, Sandell, Sonsini, Walker and Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence and Landsman is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

    The principal business of GEO and NEA 17 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 17 is to act as the sole general partner of NEA 17. The principal business of NEA 17 LLC is to act as the sole general partner of NEA Partners 17. The principal business of each of the Managers is to manage the Control Entities, GEO and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    GEO and NEA 17 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 17 and NEA Partners 17 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 3 of 10 Pages    

     

     

     

     

     

    Item 4.Purpose of Transaction.

     

    Not applicable.

     

     

     

    Item 5.Interest in Securities of the Issuer.

     

    Each of the Reporting Persons have ceased to own beneficially five percent (5%) or more of the Issuer’s Common Stock.

     

     

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

    Exhibit 3 – Power of Attorney on behalf of Liza Landsman regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 4 of 10 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 3rd day of February, 2023.

     

     

    GROWTH EQUITY OPPORTUNITIES 17, LLC

     

    By:NEW ENTERPRISE ASSOCIATES 17, L.P.
    Sole Member

     

    By:NEA PARTNERS 17, L.P.

    General Partner

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                               

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEW ENTERPRISE ASSOCIATES 17, L.P.

     

    By:NEA PARTNERS 17, L.P.
    General Partner

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEA PARTNERS 17, L.P.

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEA 17 GP, LLC

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 5 of 10 Pages    

     

     

     

     

                            *                              

    Forest Baskett

     

     

                            *                             

    Ali Behbahani

     

     

                            *                             

    Carmen Chang

     

     

                            *                             

    Anthony A. Florence, Jr.

     

     

                            *                             

    Liza Landsman

     

     

                            *                             

    Mohamad H. Makhzoumi

     

     

                            *                             

    Joshua Makower

     

     

                            *                             

    Edward T. Mathers

     

     

                            *                             

    Scott D. Sandell

     

     

                            *                             

    Peter W. Sonsini

     

     

                            *                             

    Paul Walker

     

     

                            *                             

    Rick Yang

     

     

    */s/ Louis S. Citron                        

    Louis S. Citron

    As attorney-in-fact

     

     

    This Amendment No. 1 to Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

    CUSIP No. 374163103

    13D Page 6 of 10 Pages    

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Geron Corporation.

     

    EXECUTED this 3rd day of February, 2023.

     

     

    GROWTH EQUITY OPPORTUNITIES 17, LLC

     

    By:NEW ENTERPRISE ASSOCIATES 17, L.P.
    Sole Member

     

    By:NEA PARTNERS 17, L.P.

    General Partner

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                               

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEW ENTERPRISE ASSOCIATES 17, L.P.

     

    By:NEA PARTNERS 17, L.P.
    General Partner

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEA PARTNERS 17, L.P.

     

    By:NEA 17 GP, LLC
    General Partner

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

    NEA 17 GP, LLC

     

    By:                    *                              

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 7 of 10 Pages    

     

     

     

     

     

     

                            *                              

    Forest Baskett

     

     

                            *                             

    Ali Behbahani

     

     

                            *                             

    Carmen Chang

     

     

                            *                             

    Anthony A. Florence, Jr.

     

     

                            *                             

    Liza Landsman

     

     

                            *                             

    Mohamad H. Makhzoumi

     

     

                            *                             

    Joshua Makower

     

     

                            *                             

    Edward T. Mathers

     

     

                            *                             

    Scott D. Sandell

     

     

                            *                             

    Peter W. Sonsini

     

     

                            *                             

    Paul Walker

     

     

                            *                             

    Rick Yang

     

     

    */s/ Louis S. Citron                        

    Louis S. Citron

    As attorney-in-fact

     

     

    This Agreement relating to Schedule 13D was executed by Louis S. Citron on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

    CUSIP No. 374163103

    13D Page 8 of 10 Pages    

     

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 9 of 10 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

     

     

     

     

     

     

    CUSIP No. 374163103

    13D Page 10 of 10 Pages    

      

     

    EXHIBIT 3

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of herself as an individual or in her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 1st day of April, 2020.

     

     

     

    /s/ Liza Landsman                                     

    Liza Landsman

     

     

     

     

    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GERN

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    2/26/2025Buy → Neutral
    H.C. Wainwright
    11/5/2024$8.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$7.00Outperform
    Leerink Partners
    4/30/2024$4.50Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $GERN
    SEC Filings

    See more
    • SEC Form S-8 filed by Geron Corporation

      S-8 - GERON CORP (0000886744) (Filer)

      6/30/25 5:04:21 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GERON CORP (0000886744) (Filer)

      5/27/25 4:26:47 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Geron Corporation

      SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)

      5/15/25 4:57:13 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • FDA Approval for RYTELO issued to GERON CORP

      Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

      6/7/24 12:36:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Robert J. was granted 5,540 shares, increasing direct ownership by 3% to 182,844 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      7/1/25 4:53:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aggarwal Gaurav

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:07:35 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim President and CEO Bir Dawn Carter

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:06:38 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on June 17, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and

      6/18/25 4:10:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

      New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS Updates on ongoing IMpactMF and IMproveMF trials of imetelstat show progress in advancing the science of telomerase inhibition in the treatment of myelofibrosis Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by cha

      5/28/25 8:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on May 16, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest

      5/19/25 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on Geron with a new price target

      Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

      7/10/25 8:55:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by Scotiabank with a new price target

      Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

      5/8/25 8:26:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

      2/27/25 6:20:37 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      5/13/25 4:20:43 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:08 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:06 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Leadership Updates

    Live Leadership Updates

    See more
    • Geron Corporation Announces Departure of Chief Executive Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

      3/11/25 4:02:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

      11/11/24 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa

      9/9/24 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 5:46:12 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 9:31:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Geron Corporation

      SC 13G - GERON CORP (0000886744) (Subject)

      11/14/24 6:25:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Financials

    Live finance-specific insights

    See more
    • Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

      5/7/25 7:00:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants m

      3/31/25 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated tre

      2/26/25 7:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care